#United States #wellness #Greenwich, Connecticut #Brain Health #BEVIMI

Launch of BEVIMI at the Inaugural CG Well Summit

On September 15, 2025, the inaugural CG Well Summit served as the launchpad for BEVIMI, an innovative company dedicated to brain health and wellness. Spearheaded by co-founders Joel Dudley, Ph.D., and Paul Jacobson, BEVIMI aims to transform cognitive health using cutting-edge science and technology. This landmark event attracted thought leaders and key players in the consumer health and wellness sector, hosted by the prestigious financial services firm Canaccord Genuity Group.

Highlights of the Summit

Joel Dudley, the Co-Founder and President of BEVIMI, delivered the opening keynote titled “Wellness 3.0: Charting a New Path for Personalized and Preventative Health.” Dudley's message emphasized the shift from reactive sick care to proactive health care—a core tenet of BEVIMI’s philosophy. With years of expertise in genetics and precision health, Dudley showcased how advancements in artificial intelligence, advanced diagnostics, and personalized health could dramatically improve cognitive outcomes, empowering individuals to thrive in their daily lives.

In another key session, Paul Jacobson, former CEO of Thorne HealthTech, joined a prominent panel discussion. With a legacy of guiding Thorne through significant growth and expansion, Jacobson brought invaluable insights into delivering demonstrable consumer health outcomes, discussing the vital role of science-based solutions in women’s health, longevity, gut health, and brain health.

BEVIMI: Mission and Product Launch

BEVIMI's mission is to become a global leader in cognitive longevity. Located in Greenwich, Connecticut, the company is focused on developing innovative, science-backed products aimed at tackling neuroinflammation and improving cognitive performance across diverse markets. The team consists of experienced professionals, dedicated to building a robust marketplace for brain health solutions.

Announcing its first product, set to launch in early 2026, BEVIMI is targeting individuals at high risk or in preclinical stages of Alzheimer’s disease. This revolutionary product seeks to address cognitive health with a solid scientific foundation, aiming to deliver key bioactive ingredients that have been difficult to formulate until now. The product will undergo a rigorous Institutional Review Board-approved clinical study to ensure safety and efficacy, with a focus on critical biomarkers relevant to Alzheimer’s pathology.

As Jacobson stated, “Brain health is the new heart health.” Consumers are increasingly prioritizing cognitive wellness daily, and the science supporting this shift continues to advance. BEVIMI's formulation draws on evidence from clinical studies, emphasizing its commitment to high-quality, rigorously tested nutritional support.

The Future of Cognitive Health

Joel Dudley elaborated on BEVIMI’s upcoming endeavors to support consumers proactively. In addition to launching their first product, the company plans to provide education and AI-driven insights tailored for individuals confronting cognitive decline. By focusing on critical aspects such as neuroinflammation reduction and reinforcing brain health, BEVIMI is prepared to address a wide spectrum of cognitive challenges affecting people’s lives, including improving focus, mood, sleep quality, and overall mental sharpness.

Conclusion

With the solid scientific groundwork established at the CG Well Summit, BEVIMI enters the wellness market with a mission to enhance cognitive longevity and empower individuals globally. For those looking to stay informed about future offerings and the exciting development of their first product, the upcoming launches and updates can be found on their website mybevimi.com.

In an era where prioritizing brain health is paramount, BEVIMI aims to lead this essential movement, backed by evidence-based solutions and a commitment to consumer well-being.